Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2584844 | 0.83 | SCN9A (0.33) | SCN9ASMN1; SMN2PTGESKDM4ESCN5A | |
| SCHEMBL4663242 | 0.83 | SMN1; SMN2 (0.33) | SCN9ASMN1; SMN2KDM4ESCN5A | |
| Cadaverine Tartrate SCHEMBL13685410 | 0.79 | MLNR (0.31) | SCN9ASCN5A | |
| SCHEMBL2585280 | 0.75 | SCN9A (0.33) | SCN9APTGES | |
| SCHEMBL2575837 | 0.74 | SCN9A (0.34) | SCN9AKDM4EMLLT1 | |
| SCHEMBL2575840 | 0.70 | HTR2A (0.34) | SCN9ASMN1; SMN2SCN5ACYP2C9EPHX2 | |
| SCHEMBL2578780 | 0.69 | KDM4E (0.43) | KDM4E | |
| SCHEMBL507775 | 0.67 | HTR2A (0.36) | CYP2C9EPHX2 | |
| SCHEMBL13685575 | 0.67 | ENPP2 (0.32) | SCN9AMLLT1EPHX2 | |
| SCHEMBL14046025 | 0.66 | MLNR (0.35) | SCN9AMLLT1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924561-A2 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | Eli Lilly & Company (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007028083-A2 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |